

Editorial

Open <u>Access</u>

Clinical Pharmacology and Biopharmaceutics

Sudip K Das*

Director, Research and Graduate Program in Pharmaceutical Sciences, Associate Professor, Department of Pharmaceutical Sciences, Butler University, USA

Welcome to the first issue of the open access journal, Clinical Pharmacology and Biopharmaceutics. As we launch this journal, the first question that comes to mind is "why another new journal?" To objectively answer this compelling question, we have to look at the unique vision and approach to the intended content. This new journal has two main objectives; 1) bringing clinical pharmacology and biopharmaceutics together on the same platform, particularly the translational aspects, and 2) rapid and open distribution of cuttingedge research.

Clinical pharmacology is an emerging science that is based on pharmacology but specifically deals with the clinical use of drugs in patient populations. Clinical pharmacology also illustrates the understanding of pharmacokinetics as applied to the clinical situations (clinical pharmacokinetics). The area of clinical pharmacology has expanded immensely in recent years with advances in genomics and an evolving understanding of key biomarkers. Biopharmaceutics, on the other hand, is a discipline that studies the disposition of a drug in the body based on the drug's physicochemical properties and their interaction with the biological platform. Systematic investigation of the biopharmaceutical properties of a drug is essential to determine the proper route of administration and most suitable delivery system for the drug. With the adoption of the Biopharmaceutic Classification System for drugs over the past decade, we have now developed better strategies for development of formulations based on the solubility and permeability of the drugs. A newly developed paradigm, Biopharmaceutical Drug Disposition Classification System, has also integrated the physical concept of solubility and permeability to the effect of transporters and the predominate route of elimination of the drug. In the age of interdisciplinary sciences, it is prudent to integrate the clinical pharmacology and biopharmaceutics aspects to enable scientists to obtain a comprehensive profile of the physicochemical, biopharmaceutical and clinical principles, and the delivery potential and challenges of a drug.

The open access principle brings forth rapid and free access to innovative research outcomes via this journal. To achieve this aim, we have brought together an excellent Editorial Board to advice on the latest trends in clinical and bench research in the area of Clinical Pharmacology and Biopharmaceutics. We look forward to knowing your research findings and are committed to a high level of peer review of submitted manuscripts and prompt publication.

*Corresponding author: Sudip K Das, Director, Research and Graduate Program in Pharmaceutical Sciences, Associate Professor, Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Butler University, USA, Tel: 317-940-9134; Fax: 317-940-6172; E-mail: sdas@butler.edu

Received January 10, 2012; Accepted January 11, 2012; Published January 14, 2012

Citation: Das SK (2012) Clinical Pharmacology and Biopharmaceutics. Clinic Pharmacol Biopharmaceut. 1:e103. doi:10.4172/2167-065X.1000e103

Copyright: © 2012 Das SK. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.